EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access

Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients

Mehdi Goodarzi iD, Sahar Dadkhahfar iD, Faranak Yahyaei, Zahra Razzaghi, Hamideh Moravvej iD

Archives of Iranian Medicine · 2025

DOI: 10.34172/aim.33237 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Archives of Iranian Medicine, 2025. Verfasst von Mehdi Goodarzi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Pyrimidines, Piperidines, Lichen Planus, Pyrroles. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lichen planopilaris (LPP) is a rare, inflammatory condition leading to scarring alopecia, predominantly affecting middle-aged women. Traditional treatments have shown limited efficacy, highlighting the need for novel therapeutic approaches. Tofacitinib, a Janus kinase (JAK) inhibitor, has shown promise in treating various autoimmune diseases, including autoimmune dermatological disorders. This study aims to evaluate the efficacy of tofacitinib in treating patients with LPP.

Methods

We conducted a retrospective, single-center observational study at Shohadaye Tajrish Hospital, reviewing records of 74 patients with biopsy-confirmed LPP who had extensive and treatment-resistant disease. Patients were treated with tofacitinib 5 mg twice daily for at least 16 weeks. Efficacy was assessed using the LPP Activity Index (LPPAI), and adverse events were monitored.

Results

This study evaluated 74 patients with LPP, predominantly female (83.3%), with a mean age of 46.64±8.05 years. The mean LPPAI score significantly decreased from 4.61±1.26 before treatment to 1.73±1.68 after six months (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesPiperidinesLichen PlanusPyrrolesProtein Kinase InhibitorsJanus Kinase InhibitorsHumansFemaleRetrospective StudiesMiddle AgedMaleAdultTreatment OutcomeAged

Stichwörter der Autor:innen

AlopeciaAutoimmune diseasesJanus kinase inhibitorsLichen planusTofacitinib

Substanzen

tofacitinibPyrimidinesPiperidinesPyrrolesProtein Kinase InhibitorsJanus Kinase Inhibitors

Autor:innen und Institutionen

  • Skin Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ORCID-Profile: Mehdi Goodarzi, Sahar Dadkhahfar, Hamideh Moravvej

Zitieren

APA

Goodarzi, M., Dadkhahfar, S., Yahyaei, F., Razzaghi, Z., & Moravvej, H. (2025). Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients. Archives of Iranian Medicine. https://doi.org/10.34172/aim.33237

Vancouver

Goodarzi M, Dadkhahfar S, Yahyaei F, Razzaghi Z, Moravvej H. Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients. Archives of Iranian Medicine. 2025. doi:10.34172/aim.33237

BibTeX
@article{Goodarzi2025,
  author = {Goodarzi, Mehdi and Dadkhahfar, Sahar and Yahyaei, Faranak and Razzaghi, Zahra and Moravvej, Hamideh},
  title = {Efficacy and Safety of Tofacitinib in Lichen Planopilaris: A Retrospective Series of 74 Patients},
  journal = {Archives of Iranian Medicine},
  year = {2025},
  doi = {10.34172/aim.33237}
}
Kostenlos starten →